Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University~All participants have agreed to take part in this clinical study and provide informed consent~A 3 months, prospective interventional study.~Sixty ambulatory, clinically stable symptomatic patients with systolic chronic HF (≥ 4 weeks), on optimized standard medical therapy were consecutively included and randomly allocated to the ivabradine group (n=30) and non-ivabradine group (n=30).~The baseline evaluation comprised physical examination, NYHA class, 12-lead electrocardi¬ography (ECG), Echocardiography, blood sampling for laboratory measurements, including NT-Pro BNP and Neopterin.~Patients in the Ivabradine group were administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.~Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study.~Peripheral venous blood samples were drawn between 8 and 9 am after a 30-min rest in the supine position. Serum samples were frozen at -80°C until assay.~Levels of NT-Pro BNP and Neopterin were detected using ELISA kits as prescribed by manufacturer.~Statistical tests appropriate to the study will be conducted to evaluate significance of results~Results, conclusion, discussion and recommendations will be given
The aim of this study is to assess the efficacy of Ivabradine therapy in patients with congestive heart failure using the cardiac biomarkers NT-Pro BNP and Neopterin.